Delaware Governor John Carney presented HARTLON with STEM EDGE GRANT on July 21, 2022.
U.S. Patent Serial No. US 11,147, 696 B2, entitled "BIORESORBABLE SCAFFOLD HAVING SUSTAINED DRUG DELIVERY" was issued on October 19, 2021.
HARTLON's CEO, Jack Scanlon, presented the benefits of embedding a therapeutic drug inside a #resorbable #scaffold at the 2021 EuroPCRs Innovators Day
The multi-layer HARTSORB-BRS (TM) with sustained drug delivery (until the mass of the bioresorbable vascular scaffold is resorbed) was presented to health and medical experts at the 2018 ICE meeting.
U.S. Patent Serial No. 9,855,371, entitled "BIORESORBABLE STENT" was issued on January 2, 2018.
HARTLON co-authored chapter 2.3- Scaffold processing and chapter 3.1- Unlocking scaffold mechanical properties in textbook entitled "Bioresorbable Scaffolds: From Basic Concept to Clinical Applications." The textbook is available for sale from CRC Press.
HARTLON Founder & CEO presented an update on the development of the HARTSORB-BRS (TM) during the PCR Innovators Day. The thin-strut, HARTSORB-BRS is the first bioresorbable vascular scaffold to have a dual drug delivery mechanism.